Trial watch: Dendritic cell-based anticancer therapy
Status PubMed-not-MEDLINE Jazyk angličtina Země Spojené státy americké Médium electronic-ecollection
Typ dokumentu přehledy, práce podpořená grantem, časopisecké články
PubMed
25941593
PubMed Central
PMC4292311
DOI
10.4161/21624011.2014.963424
PII: 963424
Knihovny.cz E-zdroje
- Klíčová slova
- DC, dendritic cell, DC-based vaccination, FDA, Food and Drug Administration, IFN, interferon, MRC1, mannose receptor, C type 1, MUC1, mucin 1, TAA, tumor-associated antigen, TLR, Toll-like receptor, Toll-like receptor agonists, Treg, regulatory T cell, WT1, Wilms tumor 1, antigen cross-presentation, autophagy, iDC, immature DC, immunogenic cell death, mDC, mature DC, pDC, plasmacytoid DC, regulatory T cells,
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
The use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throughout the past decade. In this context, DCs are generally expanded, exposed to autologous tumor cell lysates or loaded with specific tumor-associated antigens (TAAs), and then reintroduced into patients, often in combination with one or more immunostimulatory agents. As an alternative, TAAs are targeted to DCs in vivo by means of monoclonal antibodies, carbohydrate moieties or viral vectors specific for DC receptors. All these approaches have been shown to (re)activate tumor-specific immune responses in mice, often mediating robust therapeutic effects. In 2010, the first DC-based preparation (sipuleucel-T, also known as Provenge®) has been approved by the US Food and Drug Administration (FDA) for use in humans. Reflecting the central position occupied by DCs in the regulation of immunological tolerance and adaptive immunity, the interest in harnessing them for the development of novel immunotherapeutic anticancer regimens remains high. Here, we summarize recent advances in the preclinical and clinical development of DC-based anticancer therapeutics.
Department of Medicine; Immunobiology and Yale Cancer Center; Yale University ; New Haven CT USA
Gustave Roussy Cancer Campus ; Villejuif France
Gustave Roussy Cancer Campus ; Villejuif France ; INSERM U1015 CICBT507 ; Villejuif France
Zobrazit více v PubMed
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:; http://dx.doi.org/10.1038/32588 PubMed DOI
Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-26; PMID:; http://dx.doi.org/10.1038/nature06175 PubMed DOI
Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31:563-604; PMID:; http://dx.doi.org/10.1146/annurev-immunol-020711-074950 PubMed DOI PMC
Lanzavecchia A, Sallusto F. Ralph M. Steinman 1943-2011. Cell 2011; 147:1216-7; PMID:; http://dx.doi.org/10.1016/j.cell.2011.11.040 PubMed DOI
Nussenzweig MC, Mellman I. Ralph Steinman (1943-2011). Nature 2011; 478:460; PMID:; http://dx.doi.org/10.1038/478460a PubMed DOI
Mellman I, Nussenzweig M. Retrospective. Ralph M. Steinman (1943-2011). Science 2011; 334:466; PMID:; http://dx.doi.org/10.1126/science.1215136 PubMed DOI
Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137:1142-62; PMID:; http://dx.doi.org/10.1084/jem.137.5.1142 PubMed DOI PMC
Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J, Palucka AK. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 2003; 987:180-7; PMID:; http://dx.doi.org/10.1111/j.1749-6632.2003.tb06047.x PubMed DOI
Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O’Bar A, Agouna-Deciat O, Klucar P, Thompson-Snipes L, Zurawski S, et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010; 116:1685-97; PMID:; http://dx.doi.org/10.1182/blood-2010-01-264960 PubMed DOI PMC
Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106:271-4; PMID:; http://dx.doi.org/10.1016/S0092-8674(01)00448-2 PubMed DOI
Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19:225-34; PMID:; http://dx.doi.org/10.1016/S1074-7613(03)00208-5 PubMed DOI
Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220:129-50; PMID:; http://dx.doi.org/10.1111/j.1600-065X.2007.00575.x PubMed DOI
Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, Di Pucchio T, Connolly J, Fay JW, Pascual V, et al. Dendritic cell subsets in health and disease. Immunol Rev 2007; 219:118-42; PMID:; http://dx.doi.org/10.1111/j.1600-065X.2007.00551.x PubMed DOI
Banchereau J, Pulendran B, Steinman R, Palucka K. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries? J Exp Med 2000; 192:F39-44; PMID:; http://dx.doi.org/10.1084/jem.192.12.F39 PubMed DOI PMC
Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, Rimoldi D, Cerottini JC, Banchereau J, Palucka AK. Cross-priming of naive CD8+ T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000; 192:1535-44; PMID:; http://dx.doi.org/10.1084/jem.192.11.1535 PubMed DOI PMC
Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, Zurawski S, Bosquet N, Palucka AK, Le Grand R, et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med 2012; 209:109-21; PMID:; http://dx.doi.org/10.1084/jem.20110399 PubMed DOI PMC
Jotwani R, Palucka AK, Al-Quotub M, Nouri-Shirazi M, Kim J, Bell D, Banchereau J, Cutler CW. Mature dendritic cells infiltrate the T cell-rich region of oral mucosa in chronic periodontitis: in situ, in vivo, and in vitro studies. J Immunol 2001; 167:4693-700; PMID:; http://dx.doi.org/10.4049/jimmunol.167.8.4693 PubMed DOI PMC
Matsui T, Connolly JE, Michnevitz M, Chaussabel D, Yu CI, Glaser C, Tindle S, Pypaert M, Freitas H, Piqueras B, et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 2009; 182:6815-23; PMID:; http://dx.doi.org/10.4049/jimmunol.0802008 PubMed DOI PMC
Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, Palucka KA. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000; 165:3797-803; PMID:; http://dx.doi.org/10.4049/jimmunol.165.7.3797 PubMed DOI
Rolland A, Guyon L, Gill M, Cai YH, Banchereau J, McClain K, Palucka AK. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol 2005; 174:3067-71; PMID:; http://dx.doi.org/10.4049/jimmunol.174.5.3067 PubMed DOI
Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000; 1:510-4; PMID:; http://dx.doi.org/10.1038/82763 PubMed DOI
Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296-306; PMID:; http://dx.doi.org/10.1038/nri1592 PubMed DOI
Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294:1540-3; PMID:; http://dx.doi.org/10.1126/science.1064890 PubMed DOI
Pulendran B, Palucka K, Banchereau J. Sensing pathogens and tuning immune responses. Science 2001; 293:253-6; PMID:; http://dx.doi.org/10.1126/science.1062060 PubMed DOI
Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, Fortin A, Haniffa M, Ceron-Gutierrez L, Bacon CM, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011; 365:127-38; PMID:; http://dx.doi.org/10.1056/NEJMoa1100066 PubMed DOI PMC
Lambrecht BN, Hammad H. Taking our breath away: dendritic cells in the pathogenesis of asthma. Nat Rev Immunol 2003; 3:994-1003; PMID:; http://dx.doi.org/10.1038/nri1249 PubMed DOI
Miller E, Bhardwaj N. Dendritic cell dysregulation during HIV-1 infection. Immunol Rev 2013; 254:170-89; PMID:; http://dx.doi.org/10.1111/imr.12082 PubMed DOI PMC
Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:; http://dx.doi.org/10.1038/nrc3258 PubMed DOI PMC
Richman LP, Vonderheide RH. Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking. Oncoimmunology 2014; 3:e28610; PMID:; http://dx.doi.org/10.4161/onci.28610 PubMed DOI PMC
Sandin LC, Totterman TH, Mangsbo SM. Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer. Oncoimmunology 2014; 3:e27400; PMID:; http://dx.doi.org/10.4161/onci.27400 PubMed DOI PMC
Idoyaga J, Fiorese C, Zbytnuik L, Lubkin A, Miller J, Malissen B, Mucida D, Merad M, Steinman RM. Specialized role of migratory dendritic cells in peripheral tolerance induction. J Clin Invest 2013; 123:844-54; PMID: PubMed PMC
Watkins SK, Hurwitz AA. FOXO3: a master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology 2012; 1:252-4; PMID:; http://dx.doi.org/10.4161/onci.1.2.18241 PubMed DOI PMC
Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711; PMID:; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141040 PubMed DOI
Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13:780-8; PMID:; http://dx.doi.org/10.1038/nrm3479 PubMed DOI
Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:; http://dx.doi.org/10.1146/annurev-immunol-032712-100008 PubMed DOI
Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, Gonnella R, Frati L, Faggioni A. Activation of dendritic cells by tumor cell death. Oncoimmunology 2012; 1:1218-9; PMID:; http://dx.doi.org/10.4161/onci.20428 PubMed DOI PMC
Jin P, Han TH, Ren J, Saunders S, Wang E, Marincola FM, Stroncek DF. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med 2010; 8:4; PMID:; http://dx.doi.org/10.1186/1479-5876-8-4 PubMed DOI PMC
Quah BJ, O’Neill HC. Maturation of function in dendritic cells for tolerance and immunity. J Cell Mol Med 2005; 9:643-54; PMID:; http://dx.doi.org/10.1111/j.1582-4934.2005.tb00494.x PubMed DOI PMC
Nakahara T, Moroi Y, Uchi H, Furue M. Differential role of MAPK signaling in human dendritic cell maturation and Th1Th2 engagement. J Dermatol Sci 2006; 42:1-11; PMID:; http://dx.doi.org/10.1016/j.jdermsci.2005.11.004 PubMed DOI
Hammer GE, Ma A. Molecular control of steady-state dendritic cell maturation and immune homeostasis. Annu Rev Immunol 2013; 31:743-91; PMID:; http://dx.doi.org/10.1146/annurev-immunol-020711-074929 PubMed DOI PMC
Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006; 6:476-83; PMID:; http://dx.doi.org/10.1038/nri1845 PubMed DOI
Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30:1-22; PMID:; http://dx.doi.org/10.1146/annurev-immunol-100311-102839 PubMed DOI
Maldonado-Lopez R, De Smedt T, Michel P, Godfroid J, Pajak B, Heirman C, Thielemans K, Leo O, Urbain J, Moser M. CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 1999; 189:587-92; PMID:; http://dx.doi.org/10.1084/jem.189.3.587 PubMed DOI PMC
Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, Maraskovsky E, Maliszewski CR. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A 1999; 96:1036-41; PMID:; http://dx.doi.org/10.1073/pnas.96.3.1036 PubMed DOI PMC
Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, Cheong C, Liu K, Lee HW, Park CG, et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315:107-11; PMID:; http://dx.doi.org/10.1126/science.1136080 PubMed DOI
Ueno H, Palucka AK, Banchereau J. The expanding family of dendritic cell subsets. Nat Biotechnol 2010; 28:813-5; PMID:; http://dx.doi.org/10.1038/nbt0810-813 PubMed DOI
Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, Oh S, Fay J, Pascual V, Banchereau J, et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010; 234:199-212; PMID:; http://dx.doi.org/10.1111/j.0105-2896.2009.00884.x PubMed DOI PMC
Satpathy AT, Wu X, Albring JC, Murphy KM. Re(de)fining the dendritic cell lineage. Nat Immunol 2012; 13:1145-54; PMID:; http://dx.doi.org/10.1038/ni.2467 PubMed DOI PMC
Palucka K, Banchereau J. Human dendritic cell subsets in vaccination. Curr Opin Immunol 2013; 25:396-402; PMID:; http://dx.doi.org/10.1016/j.coi.2013.05.001 PubMed DOI PMC
Klechevsky E, Banchereau J. Human dendritic cells subsets as targets and vectors for therapy. Ann N Y Acad Sci 2013; 1284:24-30; PMID:; http://dx.doi.org/10.1111/nyas.12113 PubMed DOI
Mildner A, Jung S. Development and function of dendritic cell subsets. Immunity 2014; 40:642-56; PMID:; http://dx.doi.org/10.1016/j.immuni.2014.04.016 PubMed DOI
Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, Briere F, Chaussabel D, Zurawski G, Palucka AK, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008; 29:497-510; PMID:; http://dx.doi.org/10.1016/j.immuni.2008.07.013 PubMed DOI PMC
Clausen BE, Girard-Madoux MJ. IL-10 control of dendritic cells in the skin. Oncoimmunology 2013; 2:e23186; PMID:; http://dx.doi.org/10.4161/onci.23186 PubMed DOI PMC
Sere K, Felker P, Hieronymus T, Zenke M. TGFbeta1 microenvironment determines dendritic cell development. Oncoimmunology 2013; 2:e23083; PMID:; http://dx.doi.org/10.4161/onci.23083 PubMed DOI PMC
Bachem A, Guttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, Salama A, Movassaghi K, Opitz C, Mages HW, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010; 207:1273-81; PMID:; http://dx.doi.org/10.1084/jem.20100348 PubMed DOI PMC
Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre CA, Ventre E, Vu Manh TP, Baranek T, Storset AK, Marvel J, et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207:1283-92; PMID:; http://dx.doi.org/10.1084/jem.20100223 PubMed DOI PMC
Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207:1247-60; PMID:; http://dx.doi.org/10.1084/jem.20092140 PubMed DOI PMC
Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, Keller AM, Joffre O, Zelenay S, Nye E, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207:1261-71; PMID:; http://dx.doi.org/10.1084/jem.20092618 PubMed DOI PMC
Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol 2012; 12:557-69; PMID:; http://dx.doi.org/10.1038/nri3254 PubMed DOI
Shortman K, Heath WR. The CD8+ dendritic cell subset. Immunol Rev 2010; 234:18-31; PMID:; http://dx.doi.org/10.1111/j.0105-2896.2009.00870.x PubMed DOI
Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284:1835-7; PMID:; http://dx.doi.org/10.1126/science.284.5421.1835 PubMed DOI
Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000; 1:305-10; PMID:; http://dx.doi.org/10.1038/79747 PubMed DOI
Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, Trinchieri G, O'Garra A, Liu YJ. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocytemacrophage colony-stimulating factor. J Exp Med 2002; 195:953-8; PMID:; http://dx.doi.org/10.1084/jem.20020045 PubMed DOI PMC
Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu YJ, Blazar BR, Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004; 173:4433-42; PMID:; http://dx.doi.org/10.4049/jimmunol.173.7.4433 PubMed DOI
Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; PMID:; http://dx.doi.org/10.1038/nri1936 PubMed DOI
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:; http://dx.doi.org/10.1126/science.1203486 PubMed DOI
Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:; http://dx.doi.org/10.1038/nrd3626 PubMed DOI
Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:; http://dx.doi.org/10.1016/j.immuni.2013.06.014 PubMed DOI
Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC, Gonzalez JL, Weaver J, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012; 209:495-506; PMID:; http://dx.doi.org/10.1084/jem.20111413 PubMed DOI PMC
Tomihara K, Guo M, Shin T, Sun X, Ludwig SM, Brumlik MJ, Zhang B, Curiel TJ, Shin T. Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells. J Immunol 2010; 184:6151-60; PMID:; http://dx.doi.org/10.4049/jimmunol.0903519 PubMed DOI
Chaput N, Conforti R, Viaud S, Spatz A, Zitvogel L. The Janus face of dendritic cells in cancer. Oncogene 2008; 27:5920-31; PMID:; http://dx.doi.org/10.1038/onc.2008.270 PubMed DOI
Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, Péquignot M, Casares N, Terme M, Flament C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006; 12:214-9; PMID:; http://dx.doi.org/10.1038/nm1356 PubMed DOI
Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729-41; PMID:; http://dx.doi.org/10.1016/j.immuni.2013.03.003 PubMed DOI
Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:; http://dx.doi.org/10.1126/science.1224922 PubMed DOI
Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:; http://dx.doi.org/10.1126/science.1208347 PubMed DOI
Noessner E, Brech D, Mendler AN, Masouris I, Schlenker R, Prinz PU. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. Oncoimmunology 2012; 1:1451-3; PMID:; http://dx.doi.org/10.4161/onci.21356 PubMed DOI PMC
Sisirak V, Faget J, Vey N, Blay JY, Menetrier-Caux C, Caux C, Bendriss-Vermare N. Plasmacytoid dendritic cells deficient in IFNalpha production promote the amplification of FOXP3 regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology 2013; 2:e22338; PMID:; http://dx.doi.org/10.4161/onci.22338 PubMed DOI PMC
Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:; http://dx.doi.org/10.4161/onci.22009 PubMed DOI PMC
Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111-34; PMID:; http://dx.doi.org/10.4161/onci.21494 PubMed DOI PMC
Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001; 91:2136-47; PMID:; http://dx.doi.org/10.1002/1097-0142(20010601)91:11%3c2136::AID-CNCR1242%3e3.0.CO;2-Q PubMed DOI
Ikeguchi M, Ikeda M, Tatebe S, Maeta M, Kaibara N. Clinical significance of dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 1998; 5:1185-9; PMID: PubMed
Ishigami S, Natsugoe S, Matsumoto M, Okumura H, Sakita H, Nakashima S, Takao S, Aikou T. Clinical implications of intratumoral dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 2003; 10:1237-40; PMID: PubMed
Kakeji Y, Maehara Y, Korenaga D, Tsujitani S, Haraguchi M, Watanabe A, Orita H, Sugimachi K. Prognostic significance of tumor-host interaction in clinical gastric cancer: relationship between DNA ploidy and dendritic cell infiltration. J Surg Oncol 1993; 52:207-12; PMID:; http://dx.doi.org/10.1002/jso.2930520402 PubMed DOI
Ishigami S, Aikou T, Natsugoe S, Hokita S, Iwashige H, Tokushige M, Sonoda S. Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer. Oncology 1998; 55:65-9; PMID:; http://dx.doi.org/10.1159/000011837 PubMed DOI
Okuyama T, Maehara Y, Kakeji Y, Tsuijitani S, Korenaga D, Sugimachi K. Interrelation between tumor-associated cell surface glycoprotein and host immune response in gastric carcinoma patients. Cancer 1998; 82:1468-75; PMID:; http://dx.doi.org/10.1002/(SICI)1097-0142(19980415)82:8%3c1468::AID-CNCR6%3e3.0.CO;2-5 PubMed DOI
Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Xiangming C, Iwashige H, Aridome K, Hokita S, Aikou T. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett 2000; 159:103-8; PMID:; http://dx.doi.org/10.1016/S0304-3835(00)00542-5 PubMed DOI
Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Ohro S, Tatebe S, Tsujitani S, Ikeguchi M. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol 2007; 95:123-8; PMID:; http://dx.doi.org/10.1002/jso.20612 PubMed DOI
Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, Lee JH, Sondak VK, Riker AI, Deconti RC, et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol 2008; 26:3235-41; PMID:; http://dx.doi.org/10.1200/JCO.2007.13.9048 PubMed DOI
Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, Fan J, Tang ZY. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132:293-301; PMID:; http://dx.doi.org/10.1007/s00432-006-0075-y PubMed DOI
Yin XY, Lu MD, Lai YR, Liang LJ, Huang JF. Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterology 2003; 50:1281-4; PMID: PubMed
Nakakubo Y, Miyamoto M, Cho Y, Hida Y, Oshikiri T, Suzuoki M, Hiraoka K, Itoh T, Kondo S, Katoh H. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 2003; 89:1736-42; PMID:; http://dx.doi.org/10.1038/sj.bjc.6601331 PubMed DOI PMC
Honig A, Schaller N, Dietl J, Backe J, Kammerer U. S100 as an immunohistochemically-detected marker with prognostic significance in endometrial carcinoma. Anticancer Res 2005; 25:1747-53; PMID: PubMed
Chang KC, Huang GC, Jones D, Lin YH. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res 2007; 13:6666-72; PMID:; http://dx.doi.org/10.1158/1078-0432.CCR-07-0504 PubMed DOI
Furihata M, Ohtsuki Y, Sonobe H, Araki K, Ogata T, Toki T, Ogoshi S, Tamiya T. Prognostic significance of simultaneous infiltration of HLA-DR-positive dendritic cells and tumor infiltrating lymphocytes into human esophageal carcinoma. Tohoku J Exp Med 1993; 169:187-95; PMID:; http://dx.doi.org/10.1620/tjem.169.187 PubMed DOI
Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T, Gon G, Toyoda M, Tanigawa N. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003; 104:92-7; PMID:; http://dx.doi.org/10.1002/ijc.10915 PubMed DOI
Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26:4410-7; PMID:; http://dx.doi.org/10.1200/JCO.2007.15.0284 PubMed DOI
Sautes-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, Dieu-Nosjean MC. Tumor microenvironment is multifaceted. Cancer Metastasis Rev 2011; 30:13-25; PMID:; http://dx.doi.org/10.1007/s10555-011-9279-y PubMed DOI
Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, Gaudi I, Tímár J. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007; 56:1459-69; PMID:; http://dx.doi.org/10.1007/s00262-007-0286-3 PubMed DOI PMC
Kobayashi M, Suzuki K, Yashi M, Yuzawa M, Takayashiki N, Morita T. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma. Anticancer Res 2007; 27:1137-41; PMID: PubMed
Conrad C, Gilliet M. Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: a dangerous liaison. Oncoimmunology 2013; 2:e23887; PMID:; http://dx.doi.org/10.4161/onci.23887 PubMed DOI PMC
Ishigami S, Ueno S, Matsumoto M, Okumura H, Arigami T, Uchikado Y, Setoyama T, Arima H, Sasaki K, Kitazono M, et al. Prognostic value of CD208-positive cell infiltration in gastric cancer. Cancer Immunol Immunother 2010; 59:389-95; PMID:; http://dx.doi.org/10.1007/s00262-009-0758-8 PubMed DOI PMC
Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn CM, Ensink NG, Tollenaar RA, et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005; 11:2576-82; PMID:; http://dx.doi.org/10.1158/1078-0432.CCR-04-1448 PubMed DOI
Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, Bremond A, Goddard S, Pin JJ, Barthelemy-Dubois C, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10:7466-74; PMID:; http://dx.doi.org/10.1158/1078-0432.CCR-04-0684 PubMed DOI
Jensen TO, Schmidt H, Moller HJ, Donskov F, Hoyer M, Sjoegren P, Christensen IJ, Steiniche T. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage III melanoma. Cancer 2012; 118:2476-85; PMID:; http://dx.doi.org/10.1002/cncr.26511 PubMed DOI
Labidi-Galy SI, Treilleux I, Goddard-Leon S, Combes JD, Blay JY, Ray-Coquard I, Caux C, Bendriss-Vermare N. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology 2012; 1:380-2; PMID:; http://dx.doi.org/10.4161/onci.18801 PubMed DOI PMC
Zitvogel L, Kroemer G. Targeting dendritic cell metabolism in cancer. Nat Med 2010; 16:858-9; PMID:; http://dx.doi.org/10.1038/nm0810-858 PubMed DOI
Lombardi V, Akbari O. Dendritic cell modulation as a new interventional approach for the treatment of asthma. Drug News Perspect 2009; 22:445-51; PMID: PubMed PMC
Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004; 305:200-5; PMID:; http://dx.doi.org/10.1126/science.1100369 PubMed DOI
Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475-80; PMID:; http://dx.doi.org/10.1038/nm1039 PubMed DOI
Nabel GJ. Designing tomorrow's vaccines. N Engl J Med 2013; 368:551-60; PMID:; http://dx.doi.org/10.1056/NEJMra1204186 PubMed DOI PMC
Gross CC, Wiendl H. Dendritic cell vaccination in autoimmune disease. Curr Opin Rheumatol 2013; 25:268-74; PMID:; http://dx.doi.org/10.1097/BOR.0b013e32835cb9f2 PubMed DOI
Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014; 15:e257-67; PMID:; http://dx.doi.org/10.1016/S1470-2045(13)70585-0 PubMed DOI
Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195-203; PMID:; http://dx.doi.org/10.1172/JCI31205 PubMed DOI PMC
Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790-802; PMID:; http://dx.doi.org/10.1038/nri2173 PubMed DOI
Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, Watkins SC, Todo S, Herberman RB, Lotze MT, et al. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol 2002; 2:337-49; PMID:; http://dx.doi.org/10.1046/j.1359-4117.2002.01050.x PubMed DOI
Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999; 59:4035-41; PMID: PubMed
Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004; 10:2891-901; PMID:; http://dx.doi.org/10.1158/1078-0432.CCR-03-0380 PubMed DOI
Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, Black KL, Yu JS. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 2006; 66:8887-96; PMID:; http://dx.doi.org/10.1158/0008-5472.CAN-05-3448 PubMed DOI
Endo H, Saito T, Kenjo A, Hoshino M, Terashima M, Sato T, Anazawa T, Kimura T, Tsuchiya T, Irisawa A, et al. Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients. J Hepatobiliary Pancreat Sci 2012; 19:465-75; PMID:; http://dx.doi.org/10.1007/s00534-011-0457-7 PubMed DOI
You CX, Shi M, Liu Y, Cao M, Luo R, Hermonat PL. AAV2IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: evidence for IL-12 intracrine activity in DC. Oncoimmunology 2012; 1:847-55; PMID:; http://dx.doi.org/10.4161/onci.20504 PubMed DOI PMC
Bol KF, Tel J, de Vries IJ, Figdor CG. Naturally circulating dendritic cells to vaccinate cancer patients. Oncoimmunology 2013; 2:e23431; PMID:; http://dx.doi.org/10.4161/onci.23431 PubMed DOI PMC
Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70:706-15; PMID:; http://dx.doi.org/10.1002/(SICI)1097-0215(19970317)70:6%3c706::AID-IJC13%3e3.0.CO;2-7 PubMed DOI
DeMatos P, Abdel-Wahab Z, Vervaert C, Hester D, Seigler H. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol 1998; 68:79-91; PMID:; http://dx.doi.org/10.1002/(SICI)1096-9098(199806)68:2%3c79::AID-JSO3%3e3.0.CO;2-H PubMed DOI
DeMatos P, Abdel-Wahab Z, Vervaert C, Seigler HF. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol 1998; 185:65-74; PMID:; http://dx.doi.org/10.1006/cimm.1998.1277 PubMed DOI
Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 1998; 95:9482-7; PMID:; http://dx.doi.org/10.1073/pnas.95.16.9482 PubMed DOI PMC
Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptoticnecrotic tumor cells. Int J Cancer 2001; 93:539-48; PMID:; http://dx.doi.org/10.1002/ijc.1365 PubMed DOI
Paczesny S, Beranger S, Salzmann JL, Klatzmann D, Colombo BM. Protection of mice against leukemia after vaccination with bone marrow-derived dendritic cells loaded with apoptotic leukemia cells. Cancer Res 2001; 61:2386-9; PMID: PubMed
Kokhaei P, Choudhury A, Mahdian R, Lundin J, Moshfegh A, Osterborg A, Mellstedt H. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 2004; 18:1810-5; PMID:; http://dx.doi.org/10.1038/sj.leu.2403517 PubMed DOI
Kokhaei P, Rezvany MR, Virving L, Choudhury A, Rabbani H, Osterborg A, Mellstedt H. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 2003; 17:894-9; PMID:; http://dx.doi.org/10.1038/sj.leu.2402913 PubMed DOI
Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-9; PMID:; http://dx.doi.org/10.1038/32183 PubMed DOI
Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188:1359-68; PMID:; http://dx.doi.org/10.1084/jem.188.7.1359 PubMed DOI PMC
Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1:1297-302; PMID:; http://dx.doi.org/10.1038/nm1295-1297 PubMed DOI
Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995; 18:86-94; PMID:; http://dx.doi.org/10.1097/00002371-199508000-00002 PubMed DOI
Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183:1357-65; PMID:; http://dx.doi.org/10.1084/jem.183.4.1357 PubMed DOI PMC
Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183:317-22; PMID:; http://dx.doi.org/10.1084/jem.183.1.317 PubMed DOI PMC
Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth RJ, Jr. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998; 161:2094-8; PMID: PubMed
Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183:87-97; PMID:; http://dx.doi.org/10.1084/jem.183.1.87 PubMed DOI PMC
Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Garcia-Prats MD, DeLeo AB, Lotze MT. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997; 15:94-103; PMID:; http://dx.doi.org/10.1002/stem.150094 PubMed DOI
Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5:405-11; PMID:; http://dx.doi.org/10.1038/7403 PubMed DOI
Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184:465-72; PMID:; http://dx.doi.org/10.1084/jem.184.2.465 PubMed DOI PMC
Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186:1177-82; PMID:; http://dx.doi.org/10.1084/jem.186.7.1177 PubMed DOI PMC
Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028-34; PMID: PubMed
Irvine AS, Trinder PK, Laughton DL, Ketteringham H, McDermott RH, Reid SC, Haines AM, Amir A, Husain R, Doshi R, et al. . Efficient nonviral transfection of dendritic cells and their use for in vivo immunization. Nat Biotechnol 2000; 18:1273-8; PMID:; http://dx.doi.org/10.1038/82383 PubMed DOI
Manickan E, Kanangat S, Rouse RJ, Yu Z, Rouse BT. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukoc Biol 1997; 61:125-32; PMID: PubMed
Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA, Crystal RG. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186:1247-56; PMID:; http://dx.doi.org/10.1084/jem.186.8.1247 PubMed DOI PMC
Tuting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or “self” antigens induce antitumor immunity in vivo. Eur J Immunol 1997; 27:2702-7; PMID:; http://dx.doi.org/10.1002/eji.1830271033 PubMed DOI
Wan Y, Bramson J, Carter R, Graham F, Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997; 8:1355-63; PMID:; http://dx.doi.org/10.1089/hum.1997.8.11-1355 PubMed DOI
McArthur JG, Mulligan RC. Induction of protective anti-tumor immunity by gene-modified dendritic cells. J Immunother 1998; 21:41-7; PMID:; http://dx.doi.org/10.1097/00002371-199801000-00005 PubMed DOI
Ishida T, Chada S, Stipanov M, Nadaf S, Ciernik FI, Gabrilovich DI, Carbone DP. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol 1999; 117:244-51; PMID:; http://dx.doi.org/10.1046/j.1365-2249.1999.00913.x PubMed DOI PMC
Tuting T, Steitz J, Bruck J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. J Gene Med 1999; 1:400-6; PMID:; http://dx.doi.org/10.1002/(SICI)1521-2254(199911/12)1:6%3c400::AID-JGM68%3e3.0.CO;2-D PubMed DOI
Wan Y, Emtage P, Zhu Q, Foley R, Pilon A, Roberts B, Gauldie J. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell Immunol 1999; 198:131-8; PMID:; http://dx.doi.org/10.1006/cimm.1999.1585 PubMed DOI
Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000; 191:1699-708; PMID:; http://dx.doi.org/10.1084/jem.191.10.1699 PubMed DOI PMC
Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, Amarnani SN, Glaspy JA, McBride WH, Economou JS. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 2000; 23:59-66; PMID:; http://dx.doi.org/10.1097/00002371-200001000-00008 PubMed DOI
Okada N, Saito T, Masunaga Y, Tsukada Y, Nakagawa S, Mizuguchi H, Mori K, Okada Y, Fujita T, Hayakawa T, et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001; 61:7913-9; PMID: PubMed
Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000; 165:5713-9; PMID:; http://dx.doi.org/10.4049/jimmunol.165.10.5713 PubMed DOI
Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6:1011-7; PMID:; http://dx.doi.org/10.1038/79519 PubMed DOI
Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos KG. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 2001; 94:474-81; PMID:; http://dx.doi.org/10.3171/jns.2001.94.3.0474 PubMed DOI
Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 2002; 22:613-21; PMID: PubMed
Van Meirvenne S, Straetman L, Heirman C, Dullaers M, De Greef C, Van Tendeloo V, Thielemans K. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 2002; 9:787-97; PMID:; http://dx.doi.org/10.1038/sj.cgt.7700499 PubMed DOI
Li M, You S, Ge W, Ma S, Ma N, Zhao C. Induction of T-cell immunity against leukemia by dendritic cells pulsed with total RNA isolated from leukemia cells. Chin Med J (Engl) 2003; 116:1655-61; PMID: PubMed
Minami T, Nakanishi Y, Izumi M, Harada T, Hara N. Enhancement of antigen-presenting capacity and antitumor immunity of dendritic cells pulsed with autologous tumor-derived RNA in mice. J Immunother 2003; 26:420-31; PMID:; http://dx.doi.org/10.1097/00002371-200309000-00005 PubMed DOI
Schmidt T, Ziske C, Marten A, Endres S, Tiemann K, Schmitz V, Gorschlüter M, Schneider C, Sauerbruch T, Schmidt-Wolf IG. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL6 pancreatic murine tumor model. Cancer Res 2003; 63:8962-7; PMID: PubMed
Jung CW, Kwon JH, Seol JG, Park WH, Hyun JM, Kim ES, Kim ST, Lee SJ, Kim BK, Lee YY. Induction of cytotoxic T lymphocytes by dendritic cells pulsed with murine leukemic cell RNA. Am J Hematol 2004; 75:121-7; PMID:; http://dx.doi.org/10.1002/ajh.10471 PubMed DOI
Liu BY, Chen XH, Gu QL, Li JF, Yin HR, Zhu ZG, Lin YZ. Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer. World J Gastroenterol 2004; 10:630-3; PMID: PubMed PMC
Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, Adamzik I, Kabelitz D, Dreger P, Schmitz N, et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003; 170:5391-7; PMID:; http://dx.doi.org/10.4049/jimmunol.170.11.5391 PubMed DOI
Celluzzi CM, Falo LD, Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998; 160:3081-5; PMID: PubMed
Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161:5516-24; PMID: PubMed
Tanaka H, Shimizu K, Hayashi T, Shu S. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 2002; 220:1-12; PMID:; http://dx.doi.org/10.1016/S0008-8749(03)00009-1 PubMed DOI
Orentas RJ, Schauer D, Bin Q, Johnson BD. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 2001; 213:4-13; PMID:; http://dx.doi.org/10.1006/cimm.2001.1864 PubMed DOI
Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 2003; 225:65-74; PMID:; http://dx.doi.org/10.1016/j.cellimm.2003.09.005 PubMed DOI
Sukhorukov VL, Reuss R, Endter JM, Fehrmann S, Katsen-Globa A, Gessner P, Steinbach A, Müller KJ, Karpas A, Zimmermann U, et al. A biophysical approach to the optimisation of dendritic-tumour cell electrofusion. Biochem Biophys Res Commun 2006; 346:829-39; PMID:; http://dx.doi.org/10.1016/j.bbrc.2006.05.193 PubMed DOI
Cathelin D, Nicolas A, Bouchot A, Fraszczak J, Labbe J, Bonnotte B. Dendritic cell-tumor cell hybrids and immunotherapy: what's next? Cytotherapy 2011; 13:774-85; PMID:; http://dx.doi.org/10.3109/14653249.2011.553593 PubMed DOI
Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough M, O'Donnell D, Selby P, Vile R, Melcher A. Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther 2006; 13:138-49; PMID:; http://dx.doi.org/10.1038/sj.gt.3302609 PubMed DOI
Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199:815-24; PMID:; http://dx.doi.org/10.1084/jem.20032220 PubMed DOI PMC
Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196:1627-38; PMID:; http://dx.doi.org/10.1084/jem.20021598 PubMed DOI PMC
Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194:769-79; PMID:; http://dx.doi.org/10.1084/jem.194.6.769 PubMed DOI PMC
Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, Quintin-Colonna F, Haicheur N, Amessou M, Herbelin A, Langlade-Demoyen P, et al. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 2007; 179:3371-9; PMID:; http://dx.doi.org/10.4049/jimmunol.179.5.3371 PubMed DOI
Berraondo P, Nouze C, Preville X, Ladant D, Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007; 67:8847-55; PMID:; http://dx.doi.org/10.1158/0008-5472.CAN-07-0321 PubMed DOI
Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005; 106:1278-85; PMID:; http://dx.doi.org/10.1182/blood-2005-01-0318 PubMed DOI
Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials 2012; 33:4229-39; PMID:; http://dx.doi.org/10.1016/j.biomaterials.2012.02.036 PubMed DOI
Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood 2012; 119:2284-92; PMID:; http://dx.doi.org/10.1182/blood-2011-08-373944 PubMed DOI
Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, Figdor CG, Cambi A. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 2011; 118:4111-9; PMID:; http://dx.doi.org/10.1182/blood-2011-04-346957 PubMed DOI
Tacken PJ, Ter Huurne M, Torensma R, Figdor CG. Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor trafficking. Eur J Immunol 2012; 42:1989-98; PMID:; http://dx.doi.org/10.1002/eji.201142258 PubMed DOI
Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, Lambeck AJ, Figdor CG. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011; 118:6836-44; PMID:; http://dx.doi.org/10.1182/blood-2011-07-367615 PubMed DOI
Wang B. Targeting dendritic cells in situ for breast cancer immunotherapy. Oncoimmunology 2012; 1:1398-400; PMID:; http://dx.doi.org/10.4161/onci.20982 PubMed DOI PMC
Garcia-Vallejo JJ, Unger WW, Kalay H, van Kooyk Y. Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines. Oncoimmunology 2013; 2:e23040; PMID:; http://dx.doi.org/10.4161/onci.23040 PubMed DOI PMC
Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4:594-600; PMID:; http://dx.doi.org/10.1038/nm0598-594 PubMed DOI
Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999; 147:599-610; PMID:; http://dx.doi.org/10.1083/jcb.147.3.599 PubMed DOI PMC
Viaud S, Thery C, Ploix S, Tursz T, Lapierre V, Lantz O, Zitvogel L, Chaput N. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res 2010; 70:1281-5; PMID:; http://dx.doi.org/10.1158/0008-5472.CAN-09-3276 PubMed DOI
Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 2012; 1:1074-83; PMID:; http://dx.doi.org/10.4161/onci.20897 PubMed DOI PMC
Kandalaft LE, Powell DJ, Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, et al. . Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013; 2:e22664; PMID:; http://dx.doi.org/10.4161/onci.22664 PubMed DOI PMC
Fucikova J, Rozkova D, Ulcova H, Budinsky V, Sochorova K, Pokorna K, Bartůňková J, Špíšek R. Poly I: c-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J Transl Med 2011; 9:223; PMID:; http://dx.doi.org/10.1186/1479-5876-9-223 PubMed DOI PMC
Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, Spísek R. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71:4821-33; PMID:; http://dx.doi.org/10.1158/0008-5472.CAN-11-0950 PubMed DOI
Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 2008; 31:101-12; PMID:; http://dx.doi.org/10.1097/CJI.0b013e318159f5ba PubMed DOI
Lee J, Boczkowski D, Nair S. Programming human dendritic cells with mRNA. Methods Mol Biol 2013; 969:111-25; PMID:; http://dx.doi.org/10.1007/978-1-62703-260-5_8 PubMed DOI
Blalock LT, Landsberg J, Messmer M, Shi J, Pardee AD, Haskell R, Vujanovic L, Kirkwood JM, Butterfield LH. Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology 2012; 1:287-357; PMID:; http://dx.doi.org/10.4161/onci.18628 PubMed DOI PMC
Garg NK, Dwivedi P, Prabha P, Tyagi RK. RNA pulsed dendritic cells: an approach for cancer immunotherapy. Vaccine 2013; 31:1141-56; PMID:; http://dx.doi.org/10.1016/j.vaccine.2012.12.027 PubMed DOI
Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, Kajihara M, Arihiro S, Imazu H, Arakawa H, et al. Fusions between dendritic cells and whole tumor cells as anticancer vaccines. Oncoimmunology 2013; 2:e24437; PMID:; http://dx.doi.org/10.4161/onci.24437 PubMed DOI PMC
Apostolopoulos V, Thalhammer T, Tzakos AG, Stojanovska L. Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv 2013; 2013:869718; PMID:; http://dx.doi.org/10.1155/2013/869718 PubMed DOI PMC
Vingert B, Adotevi O, Patin D, Jung S, Shrikant P, Freyburger L, Eppolito C, Sapoznikov A, Amessou M, Quintin-Colonna F, et al. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol 2006; 36:1124-35; PMID:; http://dx.doi.org/10.1002/eji.200535443 PubMed DOI
Haicheur N, Bismuth E, Bosset S, Adotevi O, Warnier G, Lacabanne V, Regnault A, Desaymard C, Amigorena S, Ricciardi-Castagnoli P, et al. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J Immunol 2000; 165:3301-8; PMID:; http://dx.doi.org/10.4049/jimmunol.165.6.3301 PubMed DOI
Copland MJ, Baird MA, Rades T, McKenzie JL, Becker B, Reck F, Tyler PC, Davies NM. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003; 21:883-90; PMID:; http://dx.doi.org/10.1016/S0264-410X(02)00536-4 PubMed DOI
van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 2004; 64:4357-65; PMID:; http://dx.doi.org/10.1158/0008-5472.CAN-04-0138 PubMed DOI
Badiee A, Davies N, McDonald K, Radford K, Michiue H, Hart D, Kato M. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine 2007; 25:4757-66; PMID:; http://dx.doi.org/10.1016/j.vaccine.2007.04.029 PubMed DOI
Yang L, Yang H, Rideout K, Cho T, Joo KI, Ziegler L, Elliot A, Walls A, Yu D, Baltimore D, et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008; 26:326-34; PMID:; http://dx.doi.org/10.1038/nbt1390 PubMed DOI PMC
Hangalapura BN, Oosterhoff D, de Groot J, Boon L, Tuting T, van den Eertwegh AJ, Gerritsen WR, van Beusechem VW, Pereboev A, Curiel DT, et al. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. Cancer Res 2011; 71:5827-37; PMID:; http://dx.doi.org/10.1158/0008-5472.CAN-11-0804 PubMed DOI
Thacker EE, Nakayama M, Smith BF, Bird RC, Muminova Z, Strong TV, Timares L, Korokhov N, O'Neill AM, de Gruijl TD, et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 2009; 27:7116-24; PMID:; http://dx.doi.org/10.1016/j.vaccine.2009.09.055 PubMed DOI PMC
Korokhov N, de Gruijl TD, Aldrich WA, Triozzi PL, Banerjee PT, Gillies SD, Curiel TJ, Douglas JT, Scheper RJ, Curiel DT. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biol Ther 2005; 4:289-94; PMID:; http://dx.doi.org/10.4161/cbt.4.3.1499 PubMed DOI
Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699-716; PMID:; http://dx.doi.org/10.4161/onci.20696 PubMed DOI PMC
Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:; http://dx.doi.org/10.4161/onci.29030 PubMed DOI PMC
Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, et al. Trial watch: toll-like receptor agonists in oncological indications. Oncoimmunology 2014; 3:e29179; PMID:; http://dx.doi.org/10.4161/onci.29179 PubMed DOI PMC
Duluc D, Joo H, Ni L, Yin W, Upchurch K, Li D, Xue Y, Klucar P, Zurawski S, Zurawski G, et al. Induction and activation of human Th17 by targeting antigens to dendritic cells via dectin-1. J Immunol 2014; 192:5776-88; PMID:; http://dx.doi.org/10.4049/jimmunol.1301661 PubMed DOI PMC
Yu CI, Becker C, Wang Y, Marches F, Helft J, Leboeuf M, Anguiano E, Pourpe S, Goller K, Pascual V, et al. Human CD1c +dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-beta. Immunity 2013; 38:818-30; PMID:; http://dx.doi.org/10.1016/j.immuni.2013.03.004 PubMed DOI PMC
Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L, Clement O, Marcheteau E, Gey A, Fraisse G, et al. Mucosal imprinting of vaccine-induced CD8(+) T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013; 5:172ra20; PMID:; http://dx.doi.org/10.1126/scitranslmed.3004888 PubMed DOI PMC
Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fucikova J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2:e25771; PMID:; http://dx.doi.org/10.4161/onci.25771 PubMed DOI PMC
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:; http://dx.doi.org/10.1056/NEJMoa1001294 PubMed DOI
Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW. Sipuleucel-T. Nat Rev Drug Discov 2010; 9:513-4; PMID:; http://dx.doi.org/10.1038/nrd3220 PubMed DOI
Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17:3520-6; PMID:; http://dx.doi.org/10.1158/1078-0432.CCR-10-3126 PubMed DOI
Galluzzi L. New immunotherapeutic paradigms for castration-resistant prostate cancer. Oncoimmunology 2013; 3:e26084; http://dx.doi.org/10.4161/onci.26084 PubMed DOI PMC
Qiu Y, Yun MM, Xu MB, Wang YZ, Yun S. Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study. Int J Clin Oncol 2013; 18:657-65; PMID:; http://dx.doi.org/10.1007/s10147-012-0434-4 PubMed DOI
Abediankenari S, Janbabaei Mollae G, Ghasemi M, Yousefzadeh Y, Bahrami M, Alimoghaddam K. Vaccination of diffuse large B- cell lymphoma patients with antigen-primed dendritic cells. Acta Med Iran 2013; 51:284-8; PMID: PubMed
Fracol M, Xu S, Mick R, Fitzpatrick E, Nisenbaum H, Roses R, Fisher C, Tchou J, Fox K, Zhang P, et al. Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS. Ann Surg Oncol 2013; 20:3233-9; PMID:; http://dx.doi.org/10.1245/s10434-013-3119-y PubMed DOI
Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, Aft RL, Cornelius LA, Trinkaus KM, Linette GP. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 2013; 123:3383-94; PMID:; http://dx.doi.org/10.1172/JCI68395 PubMed DOI PMC
Kobayashi M, Sakabe T, Abe H, Tanii M, Takahashi H, Chiba A, Yanagida E, Shibamoto Y, Ogasawara M, Tsujitani S, et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J Gastrointest Surg 2013; 17:1609-17; PMID:; http://dx.doi.org/10.1007/s11605-013-2286-2 PubMed DOI
Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 2014; 20:2433-44; PMID:; http://dx.doi.org/10.1158/1078-0432.CCR-13-2617 PubMed DOI PMC
Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 2014; 20:2457-65; PMID:; http://dx.doi.org/10.1158/1078-0432.CCR-13-3017 PubMed DOI PMC
Kobayashi M, Shimodaira S, Nagai K, Ogasawara M, Takahashi H, Abe H, Tanii M, Okamoto M, Tsujitani S, Yusa S, et al. Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunol Immunother 2014; 63:797-806; PMID:; http://dx.doi.org/10.1007/s00262-014-1554-7 PubMed DOI PMC
Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, Koido S, Homma S, Okamoto M, Takakura K, et al. Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms’ Tumor 1 (WT1)-Specific MHC Class III-Restricted Epitopes for Pancreatic Cancer. Clin Cancer Res 2014; 20:4228-39; PMID:; http://dx.doi.org/10.1158/1078-0432.CCR-14-0314 PubMed DOI
Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, Storkus WJ. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 2014; 3:e27589; PMID:; http://dx.doi.org/10.4161/onci.27589 PubMed DOI PMC
Ridolfi L, Petrini M, Granato AM, Gentilcore G, Simeone E, Ascierto PA, Pancisi E, Ancarani V, Fiammenghi L, Guidoboni M, et al. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. J Transl Med 2013; 11:135; PMID:; http://dx.doi.org/10.1186/1479-5876-11-135 PubMed DOI PMC
Reyes D, Salazar L, Espinoza E, Pereda C, Castellon E, Valdevenito R, Huidobro C, Inés Becker M, Lladser A, López MN, et al. Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. Br J Cancer 2013; 109:1488-97; PMID:; http://dx.doi.org/10.1038/bjc.2013.494 PubMed DOI PMC
Bapsy PP, Sharan B, Kumar C, Das RP, Rangarajan B, Jain M, Suresh Attili VS, Subramanian S, Aggarwal S, Srivastava M, et al. Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care. Cytotherapy 2014; 16:234-44; PMID:; http://dx.doi.org/10.1016/j.jcyt.2013.11.013 PubMed DOI
Gao D, Li C, Xie X, Zhao P, Wei X, Sun W, Liu HC, Alexandrou AT, Jones J, Zhao R, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One 2014; 9:e93886; PMID:; http://dx.doi.org/10.1371/journal.pone.0093886 PubMed DOI PMC
Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, Nascene D, Gustafson MP, Dietz AB, Clark HB, Chen W, et al. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. J Immunother Cancer 2014; 2:4; PMID:; http://dx.doi.org/10.1186/2051-1426-2-4 PubMed DOI PMC
Baek S, Kim YM, Kim SB, Kim CS, Kwon SW, Kim Y, Kim H, Lee H. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase III trial. Cell Mol Immunol 2014; PMID:; http://dx.doi.org/10.1038/cmi.2014.40 PubMed DOI PMC
Poschke I, Lovgren T, Adamson L, Nystrom M, Andersson E, Hansson J, Tell R, Masucci GV, Kiessling R. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother 2014; 63:1061-71; PMID:; http://dx.doi.org/10.1007/s00262-014-1575-2 PubMed DOI PMC
Ramanathan P, Ganeshrajah S, Raghanvan RK, Singh SS, Thangarajan R. Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer - a feasibility study. Asian Pac J Cancer Prev 2014; 15:5909-16; PMID:; http://dx.doi.org/10.7314/APJCP.2014.15.4.1633 PubMed DOI
de Rosa F, Ridolfi L, Ridolfi R, Gentili G, Valmorri L, Nanni O, Petrini M, Fiammenghi L, Granato AM, Ancarani V, et al. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy andor preleukapheresis IFN-alpha in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study. J Transl Med 2014; 12:209; PMID:; http://dx.doi.org/10.1186/1479-5876-12-209 PubMed DOI PMC
Shimizu K, Kotera Y, Aruga A, Takeshita N, Katagiri S, Ariizumi S, Takahashi Y, Yoshitoshi K, Takasaki K, Yamamoto M. Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. Hum Vaccin Immunother 2014; 10:970-6; PMID:; http://dx.doi.org/10.4161/hv.27678 PubMed DOI PMC
Hunyadi J, Andras C, Szabo I, Szanto J, Szluha K, Sipka S, Kovács P, Kiss A, Szegedi G, Altorjay I, et al. Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-a phase I-II study. Pathol Oncol Res 2013; PMID: PubMed
Shibamoto Y, Okamoto M, Kobayashi M, Ayakawa S, Iwata H, Sugie C, Mitsuishi Y, Takahashi H. Immune-maximizing (IMAX) therapy for cancer: combination of dendritic cell vaccine and intensity-modulated radiation. Mol Clin Oncol 2013; 1:649-54; PMID: PubMed PMC
Everson RG, Jin RM, Wang X, Safaee M, Scharnweber R, Lisiero DN, Soto H, Liau LM, Prins RM. Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer 2014; 2:10; PMID:; http://dx.doi.org/10.1186/2051-1426-2-10 PubMed DOI PMC
Ng L, Heck W, Lavsa S, Crowther D, Atkinson B, Xiao L, Araujo J. The lack of predictors for rapid progression in prostate cancer patients receiving sipuleucel-T. Cancers (Basel) 2013; 5:511-8; PMID:; http://dx.doi.org/10.3390/cancers5020511 PubMed DOI PMC
Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, et al. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother 2013; 62:1381-92; PMID:; http://dx.doi.org/10.1007/s00262-013-1438-2 PubMed DOI PMC
Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman Z, Vergote I, Amant F, Van Gool SW. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. Anticancer Res 2013; 33:3855-9; PMID: PubMed
Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, Vergote I, Amant F, VAN Gool SW. Wilms’ Tumor Gene 1 (WT1)-loaded dendritic cell immunotherapy in patients with uterine tumors: a phase III clinical trial. Anticancer Res 2013; 33:5495-500; PMID: PubMed
Wang D, Zhang B, Gao H, Ding G, Wu Q, Zhang J, Liao L, Chen H. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer 2014; 14:251; PMID:; http://dx.doi.org/10.1186/1471-2407-14-251 PubMed DOI PMC
Shindo Y, Hazama S, Maeda Y, Matsui H, Iida M, Suzuki N, Yoshimura K, Ueno T, Yoshino S, Sakai K, et al. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. J Transl Med 2014; 12:175; PMID:; http://dx.doi.org/10.1186/1479-5876-12-175 PubMed DOI PMC
Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tonnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013; 62:1499-509; PMID:; http://dx.doi.org/10.1007/s00262-013-1453-3 PubMed DOI PMC
Benteyn D, Van Nuffel AM, Wilgenhof S, Corthals J, Heirman C, Neyns B, Thielemans K, Bonehill A. Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int 2013; 2013:976383; PMID:; http://dx.doi.org/10.1155/2013/976383 PubMed DOI PMC
Wilgenhof S, Van Nuffel AM, Benteyn D, Corthals J, Aerts C, Heirman C, Van Riet I, Bonehill A, Thielemans K, Neyns B. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 2013; 24:2686-93; PMID:; http://dx.doi.org/10.1093/annonc/mdt245 PubMed DOI
Ren J, Di L, Song G, Yu J, Jia J, Zhu Y, Yan Y, Jiang H, Liang X, Che L, et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin Transl Oncol 2013; 15:780-8; PMID:; http://dx.doi.org/10.1007/s12094-013-1001-9 PubMed DOI
Zhong R, Han B, Zhong H. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol 2014; 35:987-94; PMID:; http://dx.doi.org/10.1007/s13277-013-1132-1 PubMed DOI
Cui Y, Yang X, Zhu W, Li J, Wu X, Pang Y. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients. Oncol Lett 2013; 6:537-41; PMID: PubMed PMC
Wang ZX, Cao JX, Wang M, Li D, Cui YX, Zhang XY, Liu JL, Li JL. Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis. Cytotherapy 2014; 16:934-45; PMID:; http://dx.doi.org/10.1016/j.jcyt.2014.02.011 PubMed DOI
Hasumi K, Aoki Y, Wantanabe R, Mann DL. Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy. Oncoimmunology 2013; 2:e26381; PMID:; http://dx.doi.org/10.4161/onci.26381 PubMed DOI PMC
Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014; 6:232ra51; PMID:; http://dx.doi.org/10.1126/scitranslmed.3008068 PubMed DOI PMC
Vassilaros S, Tsibanis A, Tsikkinis A, Pietersz GA, McKenzie IF, Apostolopoulos V. Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy 2013; 5:1177-82; PMID:; http://dx.doi.org/10.2217/imt.13.126 PubMed DOI
Ho VT, Kim HT, Kao G, Cutler C, Levine J, Rosenblatt J, Joyce R, Antin JH, Soiffer RJ, Ritz J, et al. Sequential infusion of donor derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2014; 89:1092-6; PMID:; http://dx.doi.org/10.1002/ajh.23825 PubMed DOI
Takeda T, Takeda T, Etani M, Kobayashi S, Takeda H. [The effect of immunotherapy and hyperthermia on patients with advanced or recurrent breast cancer]. Gan To Kagaku Ryoho 2013; 40:1596-9; PMID: PubMed
Liu J, Li J, Fan Y, Chang K, Yang X, Zhu W, Wu X, Pang Y. Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases. Ir J Med Sci 2014; PMID: PubMed
Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:; http://dx.doi.org/10.4161/onci.25595 PubMed DOI PMC
Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, Eric T, Laurence Z, Guido K, Lorenzo G. Trial watch: radioimmunotherapy for oncological indications. Oncoimmunology 2014; DOI: 10.4161/21624011.2014.954929 PubMed DOI PMC
Reichenbach DK, Finn OJ. Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology 2013; 2:e23429; PMID:; http://dx.doi.org/10.4161/onci.23429 PubMed DOI PMC
Wang Z, Hall MD, Rewers-Felkins KA, Quinlin IS, Wright SE. Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer. Oncoimmunology 2013; 2:e23335; PMID:; http://dx.doi.org/10.4161/onci.23335 PubMed DOI PMC
Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014; 3:e28780; PMID:; http://dx.doi.org/10.4161/onci.28780 PubMed DOI PMC
Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:; http://dx.doi.org/10.4161/onci.27297 PubMed DOI PMC
Dhodapkar MV, Dhodapkar KM. Recent advances and new opportunities for targeting human dendritic cells in situ. Oncoimmunology 2014; 3(8); DOI: 10.4161/21624011.2014.954832 PubMed DOI PMC
Dubrot J, Duraes FV, Potin L, Capotosti F, Brighouse D, Suter T, LeibundGut-Landmann S, Garbi N, Reith W, Swartz MA, et al. Lymph node stromal cells acquire peptide-MHCII complexes from dendritic cells and induce antigen-specific CD4(+) T cell tolerance. J Exp Med 2014; 211:1153-66; PMID:; http://dx.doi.org/10.1084/jem.20132000 PubMed DOI PMC
Arora P, Baena A, Yu KO, Saini NK, Kharkwal SS, Goldberg MF, Kunnath-Velayudhan S, Carreño LJ, Venkataswamy MM, Kim J, et al. A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity 2014; 40:105-16; PMID:; http://dx.doi.org/10.1016/j.immuni.2013.12.004 PubMed DOI PMC
Schraml BU, van Blijswijk J, Zelenay S, Whitney PG, Filby A, Acton SE, Rogers NC, Moncaut N, Carvajal JJ, Reis e Sousa C. Genetic tracing via DNGR-1 expression history defines dendritic cells as a hematopoietic lineage. Cell 2013; 154:843-58; PMID:; http://dx.doi.org/10.1016/j.cell.2013.07.014 PubMed DOI
Klebanoff CA, Spencer SP, Torabi-Parizi P, Grainger JR, Roychoudhuri R, Ji Y, Sukumar M, Muranski P, Scott CD, Hall JA, et al. Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells. J Exp Med 2013; 210:1961-76; PMID:; http://dx.doi.org/10.1084/jem.20122508 PubMed DOI PMC
Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, Zlobec I, Karamitopoulou E, Stachler MD, Odze RD, et al. Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity 2013; 39:1095-107; PMID:; http://dx.doi.org/10.1016/j.immuni.2013.11.003 PubMed DOI PMC
Muller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res 2014; 2:741-55; PMID:; http://dx.doi.org/10.1158/2326-6066.CIR-13-0198 PubMed DOI
Baghdadi M, Yoneda A, Yamashina T, Nagao H, Komohara Y, Nagai S, Akiba H, Foretz M, Yoshiyama H, Kinoshita I, et al. TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance. Immunity 2013; 39:1070-81; PMID:; http://dx.doi.org/10.1016/j.immuni.2013.09.014 PubMed DOI
Rao S, Tortola L, Perlot T, Wirnsberger G, Novatchkova M, Nitsch R, Sykacek P, Frank L, Schramek D, Komnenovic V, et al. A dual role for autophagy in a murine model of lung cancer. Nat Commun 2014; 5:3056; PMID:; http://dx.doi.org/10.1038/ncomms4056 PubMed DOI
Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, Chen G, Price S, Lu W, Teng X, et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 2013; 27:1447-61; PMID:; http://dx.doi.org/10.1101/gad.219642.113 PubMed DOI PMC
Rosenfeldt MT, O’Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R, et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013; 504:296-300; PMID:; http://dx.doi.org/10.1038/nature12865 PubMed DOI
Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 2011; 333:1109-12; PMID:; http://dx.doi.org/10.1126/science.1201940 PubMed DOI PMC
Ko A, Kanehisa A, Martins I, Senovilla L, Chargari C, Dugue D, Mariño G, Kepp O, Michaud M, Perfettini JL, et al. Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ 2014; 21:92-9; PMID:; http://dx.doi.org/10.1038/cdd.2013.124 PubMed DOI PMC
Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on cell death 2012. Cell Death Differ 2012; 19:107-20; PMID:; http://dx.doi.org/10.1038/cdd.2011.96 PubMed DOI PMC
Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2015:in press; PMID:; http://dx.doi.org/10.1038/cdd.2014.137 PubMed DOI PMC
Garg AD, Dudek AM, Agostinis P. Autophagy-dependent suppression of cancer immunogenicity and effector mechanisms of innate and adaptive immunity. Oncoimmunology 2013; 2:e26260; PMID:; http://dx.doi.org/10.4161/onci.26260 PubMed DOI PMC
Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, Michaud M, Kepp O, Sukkurwala AQ, Vacchelli E, et al. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology 2013; 2:e24568; PMID:; http://dx.doi.org/10.4161/onci.24568 PubMed DOI PMC
Kroemer G, Galluzzi L, Zitvogel L. Immunological effects of chemotherapy in spontaneous breast cancers. Oncoimmunology 2013; 2:e27158; PMID:; http://dx.doi.org/10.4161/onci.27158 PubMed DOI PMC
Mortenson ED, Fu YX. Anti-HER2Neu passive-aggressive immunotherapy. Oncoimmunology 2014; 3:e27296; PMID:; http://dx.doi.org/10.4161/onci.27296 PubMed DOI PMC
Moschovi M, Alexiou GA, Patereli A, Stefanaki K, Doussis-Anagnostopoulou I, Stofas A, Sfakianos G, Prodromou N. Prognostic significance of cyclin A and B1 in pediatric embryonal tumors. J Neurooncol 2011; 103:699-704; PMID:; http://dx.doi.org/10.1007/s11060-010-0451-y PubMed DOI
Andersen RS, Sorensen RB, Ritter C, Svane IM, Becker JC, thor Straten P, Andersen MH. Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors. Cancer Immunol Immunother 2011; 60:227-34; PMID:; http://dx.doi.org/10.1007/s00262-010-0933-y PubMed DOI PMC
Tyler EM, Koehne G. The emergence of WT1-specific T-cell responses following allogeneic T cell-depleted hematopoietic stem cell transplantation and low-dose donor lymphocyte infusions is associated with a graft-vs.- myeloma effect. Oncoimmunology 2013; 2:e24963; PMID:; http://dx.doi.org/10.4161/onci.24963 PubMed DOI PMC
Wang C, Xie J, Guo J, Manning HC, Gore JC, Guo N. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep 2012; 28:1301-8; PMID: PubMed PMC
Tsurumi C, Esser N, Firat E, Gaedicke S, Follo M, Behe M, Elsässer-Beile U, Grosu AL, Graeser R, Niedermann G. Non-invasive in vivo imaging of tumor-associated CD133prominin. PLoS One 2010; 5:e15605; PMID:; http://dx.doi.org/10.1371/journal.pone.0015605 PubMed DOI PMC
Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol 2014; 14:546-58; PMID:; http://dx.doi.org/10.1038/nri3713 PubMed DOI
Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007; 7:179-90; PMID:; http://dx.doi.org/10.1038/nri2038 PubMed DOI
Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-84; PMID:; http://dx.doi.org/10.1038/nrd2059 PubMed DOI
Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancertestis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5:615-25; PMID:; http://dx.doi.org/10.1038/nrc1669 PubMed DOI
Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID:; http://dx.doi.org/10.4161/onci.26621 PubMed DOI PMC
Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Herve Fridman W, Cremer I, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2014; 3:e28344; PMID:; http://dx.doi.org/10.4161/onci.28344 PubMed DOI PMC
Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013; 13:525-41; PMID:; http://dx.doi.org/10.1038/nrc3565 PubMed DOI
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:; http://dx.doi.org/10.1038/nrc2355 PubMed DOI PMC
Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9:167-81; PMID:; http://dx.doi.org/10.1038/nrc2583 PubMed DOI
Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27048; PMID:; http://dx.doi.org/10.4161/onci.27048 PubMed DOI PMC
Bevacizumab in ovarian cancer. Nat Rev Cancer 2012; 12:83; PMID:; http://dx.doi.org/10.1038/nrc3213 PubMed DOI
Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; PMID:; http://dx.doi.org/10.4161/onci.24850 PubMed DOI PMC
Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy–revisited. Nat Rev Drug Discov 2011; 10:591-600; PMID:; http://dx.doi.org/10.1038/nrd3500 PubMed DOI
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370:709-22; PMID:; http://dx.doi.org/10.1056/NEJMoa1308345 PubMed DOI
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96; PMID:; http://dx.doi.org/10.1056/NEJMoa043330 PubMed DOI
Chen G, Han G, Shen B, Li Y. GM-CSF facilitates the development of inflammation-associated colorectal carcinoma. Oncoimmunology 2014; 3:e28186; PMID:; http://dx.doi.org/10.4161/onci.28186 PubMed DOI PMC
Obermajer N, Kalinski P. Key role of the positive feedback between PGE(2) and COX2 in the biology of myeloid-derived suppressor cells. Oncoimmunology 2012; 1:762-4; PMID:; http://dx.doi.org/10.4161/onci.19681 PubMed DOI PMC
FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345:433-42; PMID:; http://dx.doi.org/10.1056/NEJM200108093450607 PubMed DOI
Ming Lim C, Stephenson R, Salazar AM, Ferris RL. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR head and neck cancer cells. Oncoimmunology 2013; 2:e24677; PMID:; http://dx.doi.org/10.4161/onci.23187 PubMed DOI PMC
Sharma S, Zhu L, Davoodi M, Harris-White M, Lee JM, St John M, Salgia R, Dubinett S. TLR3 agonists and proinflammatory antitumor activities. Expert Opin Ther Targets 2013; 17:481-3; PMID:; http://dx.doi.org/10.1517/14728222.2013.781585 PubMed DOI PMC
Nicodemus CF, Berek JS. TLR3 agonists as immunotherapeutic agents. Immunotherapy 2010; 2:137-40; PMID:; http://dx.doi.org/10.2217/imt.10.8 PubMed DOI
Gujar SA, Clements D, Lee PW. Two is better than one: complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. Oncoimmunology 2014; 3:e27622; PMID:; http://dx.doi.org/10.4161/onci.27622 PubMed DOI PMC
Waldron TJ, Quatromoni JG, Karakasheva TA, Singhal S, Rustgi AK. Myeloid derived suppressor cells: targets for therapy. Oncoimmunology 2013; 2:e24117; PMID:; http://dx.doi.org/10.4161/onci.24117 PubMed DOI PMC
Hotz C, Bourquin C. Systemic cancer immunotherapy with Toll-like receptor 7 agonists: timing is everything. Oncoimmunology 2012; 1:227-8; PMID:; http://dx.doi.org/10.4161/onci.1.2.18169 PubMed DOI PMC
Demaria S, Vanpouille-Box C, Formenti SC, Adams S. The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. Oncoimmunology 2013; 2:e25997; PMID:; http://dx.doi.org/10.4161/onci.25997 PubMed DOI PMC
Li ZJ, Sohn KC, Choi DK, Shi G, Hong D, Lee HE, Whang KU, Lee YH, Im M, Lee Y, et al. Roles of TLR7 in activation of NF-kappaB signaling of keratinocytes by imiquimod. PLoS One 2013; 8:e77159; PMID:; http://dx.doi.org/10.1371/journal.pone.0077159 PubMed DOI PMC
Holcmann M, Drobits B, Sibilia M. How imiquimod licenses plasmacytoid dendritic cells to kill tumors. Oncoimmunology 2012; 1:1661-3; PMID:; http://dx.doi.org/10.4161/onci.22033 PubMed DOI PMC
Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, Colonna M, Sibilia M. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012; 122:575-85; PMID:; http://dx.doi.org/10.1172/JCI61034 PubMed DOI PMC
Okuyama R, Aruga A, Hatori T, Takeda K, Yamamoto M. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Oncoimmunology 2013; 2:e27010; PMID:; http://dx.doi.org/10.4161/onci.27010 PubMed DOI PMC
Suri A, Saini S, Sinha A, Agarwal S, Verma A, Parashar D, Singh S, Gupta N, Jagadish N. Cancer testis antigens: a new paradigm for cancer therapy. Oncoimmunology 2012; 1:1194-6; PMID:; http://dx.doi.org/10.4161/onci.20686 PubMed DOI PMC
Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, Mooney SM, Getzenberg RH. Cancertestis antigens and urological malignancies. Nat Rev Urol 2012; 9:386-96; PMID:; http://dx.doi.org/10.1038/nrurol.2012.117 PubMed DOI PMC
Sznurkowski JJ, Zawrocki A, Karczewska J, Emerich J, Biernat W. Should we consider cancertestis antigens NY-ESO-1, MAGE-A4 and MAGE-A1 as potential targets for immunotherapy in vulvar squamous cell carcinoma? Histopathology 2011; 58:481-3; PMID:; http://dx.doi.org/10.1111/j.1365-2559.2011.03772.x PubMed DOI
Turksma AW, Bontkes HJ, Ruizendaal JJ, Scholten KB, Akershoek J, Rampersad S, Moesbergen LM, Cillessen SA, Santegoets SJ, de Gruijl TD, et al. Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med 2013; 11:152; PMID:; http://dx.doi.org/10.1186/1479-5876-11-152 PubMed DOI PMC
Manuel ER, Blache CA, Ellenhorn JD, Diamond DJ. Survivin the battle against immunosuppression. Oncoimmunology 2012; 1:240-1; PMID:; http://dx.doi.org/10.4161/onci.1.2.18180 PubMed DOI PMC
Altieri DC. Targeting survivin in cancer. Cancer Lett 2013; 332:225-8; PMID:; http://dx.doi.org/10.1016/j.canlet.2012.03.005 PubMed DOI PMC
Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. J Transl Med 2013; 11:83; PMID:; http://dx.doi.org/10.1186/1479-5876-11-83 PubMed DOI PMC
Rutella S, Locatelli F. Is there a role for cytokine-induced killer cells in cancer immunotherapy? Immunotherapy 2012; 4:867-9; PMID:; http://dx.doi.org/10.2217/imt.12.89 PubMed DOI
Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2011; 2:363-8; PMID:; http://dx.doi.org/10.7150/jca.2.363 PubMed DOI PMC
Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; PMID:; http://dx.doi.org/; http://dx.doi.org/10.4161/onci.24238 PubMed DOI PMC
Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306-15; PMID:; http://dx.doi.org/10.4161/onci.19549 PubMed DOI PMC
Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013; 2:e23033; PMID:; http://dx.doi.org/10.4161/onci.23033 PubMed DOI PMC
Vogelzang NJ. Enzalutamide–a major advance in the treatment of metastatic prostate cancer. N Engl J Med 2012; 367:1256-7; PMID:; http://dx.doi.org/10.1056/NEJMe1209041 PubMed DOI
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-97; PMID:; http://dx.doi.org/10.1056/NEJMoa1207506 PubMed DOI
Raymond E, Dalgleish A, Damber JE, Smith M, Pili R. Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol 2014; 73:1-8; PMID:; http://dx.doi.org/10.1007/s00280-013-2321-8 PubMed DOI PMC
Osanto S, van Poppel H, Burggraaf J. Tasquinimod: a novel drug in advanced prostate cancer. Future Oncol 2013; 9:1271-81; PMID:; http://dx.doi.org/10.2217/fon.13.136 PubMed DOI
George S, Pili R. Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer. Curr Oncol Rep 2013; 15:65-8; PMID:; http://dx.doi.org/10.1007/s11912-013-0295-7 PubMed DOI
Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC, et al. Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR NK cell levels correlate with disease outcome. Oncoimmunology 2013; 2:e23080; PMID:; http://dx.doi.org/10.4161/onci.23080 PubMed DOI PMC
Pautier P, Locher C, Robert C, Deroussent A, Flament C, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, et al. Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate. Oncoimmunology 2013; 2:e23079; PMID:; http://dx.doi.org/10.4161/onci.23079 PubMed DOI PMC
Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2013; 2:e26527; PMID:; http://dx.doi.org/10.4161/onci.26527 PubMed DOI PMC
Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012; 366:2008-16; PMID:; http://dx.doi.org/10.1056/NEJMct1114348 PubMed DOI
Riedmann EM. CDX-1401 combined with TLR agonist: positive phase 1 results. Hum Vaccin Immunother 2012; 8:1742 PubMed
Riediger C, Wingender G, Knolle P, Aulmann S, Stremmel W, Encke J. Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALBc mouse model. J Cancer Res Clin Oncol 2013; 139:2097-110; PMID:; http://dx.doi.org/10.1007/s00432-013-1532-z PubMed DOI PMC
Valaperti A, Nishii M, Germano D, Liu PP, Eriksson U. Vaccination with Flt3L-induced CD8alpha+ dendritic cells prevents CD4+ T helper cell-mediated experimental autoimmune myocarditis. Vaccine 2013; 31:4802-11; PMID:; http://dx.doi.org/10.1016/j.vaccine.2013.07.084 PubMed DOI
Kretz-Rommel A, Qin F, Dakappagari N, Torensma R, Faas S, Wu D, Bowdish KS. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother 2007; 30:715-26; PMID:; http://dx.doi.org/10.1097/CJI.0b013e318135472c PubMed DOI
Pereira CF, Torensma R, Hebeda K, Kretz-Rommel A, Faas SJ, Figdor CG, Adema GJ. In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model. J Immunother 2007; 30:705-14; PMID:; http://dx.doi.org/10.1097/CJI.0b013e31812e6256 PubMed DOI
Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, et al. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother 2013; 36:152-7; PMID:; http://dx.doi.org/10.1097/CJI.0b013e3182811ae4 PubMed DOI PMC
Dannull J, Haley NR, Archer G, Nair S, Boczkowski D, Harper M, De Rosa N, Pickett N, Mosca PJ, Burchette J, et al. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest 2013; 123:3135-45; PMID:; http://dx.doi.org/10.1172/JCI67544 PubMed DOI PMC
Lactate from the tumor microenvironment - A key obstacle in NK cell-based immunotherapies
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
Trial Watch-Immunostimulation with cytokines in cancer therapy
Trial watch: Naked and vectored DNA-based anticancer vaccines
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
